Taking people in Hollandia4. fázis
PROMISE
Key facts
- Where
- Amsterdam, Groningen, Leeuwarden és Zwolle, HollandiaSee the 4 sites
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMCAmsterdam, HollandiaTaking people
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
- Medisch Centrum Leeuwarden B.V.Leeuwarden, HollandiaTaking people
- Isala Klinieken StichtingZwolle, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Groningen
- Trial code
- EU 2023-505626-34-01
- Record updated
- 2025. december 12.
- Original description
To demonstrate that patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with CKD stage 3b/4, resulting in a significant reduction in albuminuria.Read full original descriptionShow less
PROMISE: Potassium correction for RAAS Optimization in Chronic Kidney Disease
To demonstrate that patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with CKD stage 3b/4, resulting in a significant reduction in albuminuria.
Inclusion: Age ≥ 18 years; CKD stage 3b-4 (eGFR 15-44 mL/min/1.73 m2 - Albumin-creatinine ratio >3 mg/mmol - Systolic blood pressure >130 mmHg or use of one or more antihypertensive drugs; Serum K+ 4.0-5.0 mmol/L; On sub-maximal dose ACEi/ARB.
Exclusion: Prior ACEi/ARB dose reduction due to a drop in eGFR by >25% in the last year; history of severe hyperkalaemia (>6.0 mmol/L) in the last year; pregnancy or breastfeeding; life expectancy <12 months.